March 27th 2025
Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.
Islet Transplants Improve Glucose Control Yet Still Fall Short
September 27th 2006EDMONTON, Alberta -- Two years after receiving transplants of insulin-producing beta islet cells, only five of 36 patients with type 1 diabetes remained free of the need for insulin injections, reported investigators in a small multinational trial.
Oral Agents for Diabetes Complicated by Renal Disease and CHF
September 15th 2006In patients with diabetes who have end-stage renal disease and CHF, the choice of oral medications is limited because metformin is contraindicated. Glipizide has a 5% renal clearance and is relatively safe. Studies suggest that glimepiride is the safest of the sulfonylureas.
ASNC: Coronary Calcium Score Predicts Vascular Disease in Asymptomatic Type 2 Diabetes
September 12th 2006MONTREAL -- A coronary artery calcium score, obtained via CT, can accurately predict the development of atherosclerotic and ischemic disease in asymptomatic patients with type 2 diabetes, according to a report at the American Society of Nuclear cardiology meeting here.
Early-Onset of Type 2 Diabetes Linked to Early Death
July 25th 2006PHOENIX, Ariz. -- The onset of type 2 diabetes before age 20 in Pima Indians, who are genetically prone to the disease, was associated with an increased risk of early kidney failure and death between ages 25 to 55, researchers reported.
Lifestyle Can Fend off Type 2 Diabetes Genetic Risk
July 20th 2006BOSTON -- Two common genetic variants appear to contribute to the development of type 2 diabetes for some patients with impaired glucose tolerance, found researchers here. But lifestyle moves seem to be able to combat the enhanced risk.
ADA: Investigational Type 2 Diabetes Drug Lowers Weight and Improves Insulin Function
June 13th 2006WASHINGTON - Liraglutide, an investigational injectable drug for type 2 diabetes, has produced significant decreases in HbA1c levels, as well as significant and sustained weight loss, according to phase 2 studies.
ADA: Investigational Januvia Put Through Its Paces for Diabetes
June 11th 2006WASHINGTON ? Januvia (sitagliptin), an investigational oral agent for type 2 diabetes, appears to be effective when given as a monotherapy or as an adjunct to Glucophage (metformin) or Actos (pioglitazone), reported researchers here.